Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Welt, G. Ritter, Clarence Williams, L. Cohen, A. Jungbluth, Elizabeth Richards, L. Old, N. Kemeny (2003)
Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 4
J. Murray, D. Macey, L. Kasi, P. Rieger, J. Cunningham, V. Bhadkamkar, Huazhong Zhang, J. Schlom, M. Rosenblum, D. Podoloff (1994)
Phase II radioimmunotherapy trial with 131I‐CC49 in colorectal cancerCancer, 73
M. D'Huyvetter, Jens Vos, C. Xavier, M. Pruszyński, Yann Sterckx, Sam Massa, G. Raes, V. Caveliers, M. Zalutsky, T. Lahoutte, N. Devoogdt (2017)
131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer TreatmentClinical Cancer Research, 23
N. Cheung, B. Landmeier, John Neely, A. Nelson, C. Abramowsky, S. Ellery, Robert Adams, F. Miraldi (1986)
Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice.Journal of the National Cancer Institute, 77 3
M. Kameswaran, V. Gota, R. Ambade, Sudeep Gupta, A. Dash (2016)
Preparation and preclinical evaluation of 131 I-trastuzumab for breast cancer.Journal of labelled compounds & radiopharmaceuticals, 60 1
S. Welt, A. Scott, C. Divgi, N. Kemeny, R. Finn, F. Daghighian, J. Germain, E. Richards, S. Larson, L. Old (1994)
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 6
R. Muraro, M. Kuroki, D. Wunderlich, D. Poole, D. Colcher, A. Thor, J. Greiner, J. Simpson, A. Molinolo, P. Noguchi, J. Schlom, R Nih (1988)
Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.Cancer research, 48 16
D. Colcher, Maria Minelli, M. Roselli, R. Muraro, Diane Simpson-Milenic, J. Schlom (1988)
Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies.Cancer research, 48 16
D. Goldenberg, F. Deland, S. Bennett, F. Primus, M. Nelson, R. Flanigan, J. Mcroberts, A. Bruce, D. Mahan (1983)
Radioimmunodetection of prostatic cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging.JAMA, 250 5
A. Epstein, David Chen, A. Ansari, A. Najafi, M. Siegel, Kai Lee, E. Hu, P. Rosen, K. Watkins, S. Stain, F. Weaver, C. Taylor (1991)
Radioimmunodetection of necrotic lesions in human tumors using I-131 labeled TNT-1 F(ab')2 monoclonal antibody, 4
A Epenetos, J Shepherd, K Britton, S Mather, J Taylor-Papadimitriou, M Granowska (1985)
I-123 Radioiodinated antibody imaging of occult ovarian-cancerCancer, 55
Lu Wu, Yefa Yang, N. Ge, Shuqun Shen, Jun Liang, Yi Wang, Weiping Zhou, F. Shen, Meng‐chao Wu (2012)
Hepatic artery injection of 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 39
Michael Leahy, J. Turner (2011)
Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.Blood, 117 1
(1995)
Initial turner targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal-antibody PAM4 in patients with pancreatic-cancer
M. Bourdon, R. Coleman, R. Blasberg, D. Groothuis, D. Bigner (1984)
Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis.Anticancer research, 4 3
A. Cohen, E. Martin, I. Lavery, J. Daly, A. Sardi, D. Aitken, K. Bland, C. Mojzisik, G. Hinkle (1991)
Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer.Archives of surgery, 126 3
W. Buijs, J. Tibben, O. Boerman, C. Molthoff, L. Massuger, E. Koenders, C. Schijf, J. Siegel, F. Corstens (1998)
Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administrationEuropean Journal of Nuclear Medicine, 25
O. Press, J. Unger, R. Braziel, D. Maloney, T. Miller, M. LeBlanc, R. Fisher (2006)
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 25
Richard Wahl, K. Zasadny, David Macfarlane, I. Francis, Charles Ross, J. Estes, Susan Fisher, David Regan, S. Kroll, M. Kaminski (1998)
Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 39 8 Suppl
A. McQuillan, W. Macdonald, M. Leahy, J. Turner (2011)
First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with 131I-Rituximab: The INITIAL Study,Blood, 118
S. Brack, M. Silacci, M. Birchler, D. Neri (2006)
Tumor-Targeting Properties of Novel Antibodies Specific to the Large Isoform of Tenascin-CClinical Cancer Research, 12
A. Scott, F. Lee, Robert Jones, W. Hopkins, D. MacGregor, J. Cebon, A. Hannah, G. Chong, P. U, A. Papenfuss, A. Rigopoulos, S. Sturrock, R. Murphy, Veronika Wirth, C. Murone, F. Smyth, S. Knight, S. Welt, G. Ritter, Elizabeth Richards, E. Nice, A. Burgess, L. Old (2005)
A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor UptakeClinical Cancer Research, 11
Luther Brady, Arnold Markoe, David Woo, M. Rackover, H. Koprowski, Z. Steplewski, Robert Peyster (1990)
Iodine125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas. A pilot study.Journal of neurosurgical sciences, 34 3-4
Christina Ebbinghaus, Jörg Scheuermann, D. Neri, G. Elia (2004)
Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis.Current pharmaceutical design, 10 13
R Meredith, M Khazaeli, W Plott, W Grizzle, T Liu, J Schlom (1996)
Phase II study of dual I-131-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancerClin Cancer Res, 2
Adjuvant I - 131 - metuximab for hepatocellular carcinoma after liver resection : a randomised , controlled , multicentre , open - label , phase 2 trial
D. Bigner, Mark Brown, A. Friedman, R. Coleman, G. Akabani, H. Friedman, W. Thorstad, R. McLendon, S. Bigner, Xiaoguang Zhao, C. Pegram, C. Wikstrand, J. Herndon, N. Vick, N. Paleologos, I. Cokgor, J. Provenzale, M. Zalutsky (1998)
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 6
D. Reardon, J. Quinn, G. Akabani, R. Coleman, A. Friedman, H. Friedman, J. Herndon, R. McLendon, C. Pegram, J. Provenzale, J. Dowell, J. Rich, J. Vredenburgh, A. Desjardins, J. Sampson, S. Gururangan, T. Wong, M. Badruddoja, Xiaoguang Zhao, D. Bigner, M. Zalutsky (2006)
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 47 6
(1981)
Intra - cerebral metastases in solid - tumour patients — natural - history and results of treatment
L. Mantovani, S. Miotti, S. Ménard, S. Canevari, F. Raspagliesi, C. Bottini, F. Bottéro, M. Colnaghi (1994)
Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19.European journal of cancer, 30A 3
Sandra Gendler (2001)
MUC1, The Renaissance MoleculeJournal of Mammary Gland Biology and Neoplasia, 6
R. Meredith, M. Khazaeli, W. Plott, M. Saleh, Tiepu Liu, Laquetta Allen, C. Russell, R. Orr, D. Colcher, J. Schlom, D. Shochat, R. Wheeler, A. Lobuglio (1992)
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 33 1
C. Xavier, I. Vaneycken, M. D'Huyvetter, Johannes Heemskerk, M. Keyaerts, C. Vincke, N. Devoogdt, S. Muyldermans, T. Lahoutte, V. Caveliers (2013)
Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in CancerThe Journal of Nuclear Medicine, 54
D. Berndorff, S. Borkowski, S. Sieger, Axel Rother, M. Friebe, F. Viti, C. Hilger, J. Cyr, L. Dinkelborg (2005)
Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited RadioimmunoconjugateClinical Cancer Research, 11
A. Markoe, L. Brady, D. Woo, B. Amendola, U. Karlsson, S. Fisher, B. Micaily, M. Rackover, S. Bulova, Z. Steplewski, H. Koprowski (1990)
Treatment of gastrointestinal cancer using monoclonal antibodies.Frontiers of radiation therapy and oncology, 24
D. Matthias, Huyvetter, J. Vos, V. Caveliers, I. Vaneycken, Johannes Heemskerk, F. Duhoux, C. Fontaine, M. Vanhoeij, A. Windhorst, F. Aa, N. Hendrikse, J. Eersels, H. Everaert, Pieterjan Gykiere, N. Devoogdt, G. Raes, T. Lahoutte, M. Keyaerts (2020)
Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer PatientsThe Journal of Nuclear Medicine, 62
A. Epenetos, A. Epenetos, S. Mather, S. Mather, M. Granowska, M. Granowska, C. Nimmon, C. Nimmon, L. Hawkins, L. Hawkins, K. Britton, K. Britton, J. Shepherd, J. Shepherd, J. Taylor‐Papadimitriou, J. Taylor‐Papadimitriou, H. Durbin, H. Durbin, J. Malpas, J. Malpas, W. Bodmer, W. Bodmer (1982)
TARGETING OF IODINE-123-LABELLED TUMOUR-ASSOCIATED MONOCLONAL ANTIBODIES TO OVARIAN, BREAST, AND GASTROINTESTINAL TUMOURSThe Lancet, 320
K. Bouchelouche, B. Turkbey, P. Choyke (2016)
PSMA PET and Radionuclide Therapy in Prostate Cancer.Seminars in nuclear medicine, 46 6
V. Johnson, J. Schlom, A. Paterson, J. Bennett, J. Magnani, D. Colcher (1986)
Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3.Cancer research, 46 2
K. Dobrenkov, N. Cheung (2014)
GD2-targeted immunotherapy and radioimmunotherapy.Seminars in oncology, 41 5
C. Kosmas, H. Kalofonos, V. Hird, A. Epenetos (1998)
Monoclonal Antibody Targeting of Ovarian CarcinomaOncology, 55
C. Divgi, A. Scott, K. McDermott, P. Fallone, S. Hilton, K. Siler, N. Carmichael, F. Daghighian, R. Finn, A. Cohen (1994)
Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen.Nuclear medicine and biology, 21 1
H. Hansen, E. Newman, R. Grebenau, D. Goldenberg, R. Sharkey (1993)
Characterization of second‐generation monoclonal antibodies against carcinoembryonic antigenCancer, 71
A. McQuillan, W. Macdonald, J. Turner (2015)
Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.Leukemia & lymphoma, 56 5
S. Welt, C. Divgi, Francisco Real, Samuel Yeh, P. Garin‐Chesa, C. Finstad, Junichi Sakamoto, Alfred Cohen, Elin Sigurdson, N. Kemeny (1990)
Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 11
R. Rijswijk, K. Hoekman, C. Burger, R. Verheijen, J. Vermorken (1997)
Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.Annals of oncology : official journal of the European Society for Medical Oncology, 8 12
L Santoro, S Boutaleb, V Garambois, C Bascoul-Mollevi, V Boudousq, P Kotzki (2009)
Noninternalizing monoclonal antibodies are suitable candidates for I-125 radioimmunotherapy of small-volume peritoneal carcinomatosisJ Nucl Med, 50
R. Meredith, A. Bueschen, M. Khazaeli, W. Plott, W. Grizzle, R. Wheeler, J. Schlom, C. Russell, Tiepu Liu, A. Lobuglio (1994)
Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 35 6
C Lu-Emerson, AF Eichler (2012)
Brain metastasesContinuum Lifelong Learn Neurol, 18
J. Sitzmann, R. Abrams (1993)
Improved survival for hepatocellular cancer with combination surgery and multimodality treatment.Annals of surgery, 217 2
Hilary Street, M. Goris, G. Fisher, B. Wessels, C. Cho, C. Hernández, H. Zhu, Yuxia Zhang, J. Nangiana, J. Shan, K. Roberts, S. Knox (2006)
Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer.Cancer biotherapy & radiopharmaceuticals, 21 3
D. Slavin-Chiorini, S. Kashmiri, Hyun-Sil Lee, D. Milenic, D. Poole, Eric Bernon, J. Schlom, P. Hand (1997)
A CDR-grafted (humanized) domain-deleted antitumor antibody.Cancer biotherapy & radiopharmaceuticals, 12 5
B. Mueller, R. Reisfeld, S. Gillies (1990)
Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.Proceedings of the National Academy of Sciences of the United States of America, 87
G. Akabani, I. Cokgor, R. Coleman, D. Trotter, T. Wong, H. Friedman, A. Friedman, Ana Garcia-Turner, J. Herndon, D. DeLong, R. McLendon, Xiaoguang Zhao, C. Pegram, J. Provenzale, D. Bigner, M. Zalutsky (2000)
Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.International journal of radiation oncology, biology, physics, 46 4
M. Hens, G. Vaidyanathan, Xiaoguang Zhao, D. Bigner, M. Zalutsky (2010)
Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.Nuclear medicine and biology, 37 7
S. Denardo, C. Richman, D. Goldstein, S. Shen, Q. Salako, D. Kukis, C. Meares, A. Yuan, J. Welborn, G. Denardo (1997)
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.Anticancer research, 17 3B
V. Papanastassiou, B. Pizer, H. Coakham, J. Bullimore, T. Zananiri, J. Kemshead (1993)
Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry.British Journal of Cancer, 67
T. Behr, R. Sharkey, M. Juweid, R. Dunn, R. Vagg, Z. Ying, Cun-Hui Zhang, L. Swayne, Y. Vardi, J. Siegel, D. Goldenberg (1997)
Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 38 6
P. Riva, Giancarlo Franceschi, M. Frattarelli, N. Riva, G. Guiducci, A. Cremonini, G. Giuliani, M. Casi, R. Gentile, Annti Jekunen, K. Kairemo (1999)
131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study.Acta oncologica, 38 3
D. Colcher, D. Milenic, M. Roselli, A. Raubitschek, G. Yarranton, D. King, J. Adair, N. Whittle, M. Bodmer, J. Schlom (1989)
Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.Cancer research, 49 7
D. King, P. Antoniw, RJ Owens, JR Adair, Amr Haines, Aph Farnsworth, H. Finney, A. Lawson, A. Lyons, T. Baker (1995)
Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.British Journal of Cancer, 72
(1985)
I-131 antiferritin, a new treatment modality in hepatoma—a radiation-therapy-oncology-group study
V. Hird, A. Maraveyas, D. Snook, B. Dhokia, W. Soutter, C. Meares, J. Stewart, P. Mason, Hernán Lambert, A. Epenetos (1974)
Asbestos fibers in the colonic wall.Environmental Health Perspectives, 9
J. Greiner, F. Guadagni, D. Goldstein, E. Borden, R. Ritts, P. Witt, A. Lobuglio, M. Saleh, J. Schlom (1991)
Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons.Cancer research, 51 16
F. Crippa, G. Bolis, E. Seregni, N. Gavoni, G. Scarfone, C. Ferraris, G. Buraggi, E. Bombardieri (1995)
Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer.European journal of cancer, 31A 5
A. Yu, A. Gilman, M. Ozkaynak, W. London, S. Kreissman, Helen Chen, Malcolm Smith, B. Anderson, J. Villablanca, K. Matthay, H. Shimada, S. Grupp, R. Seeger, C. Reynolds, A. Buxton, R. Reisfeld, S. Gillies, S. Cohn, J. Maris, P. Sondel (2010)
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.The New England journal of medicine, 363 14
S. Sacchi, L. Marcheselli, A. Bari, R. Marcheselli, S. Pozzi, S. Luminari, M. Lombardo, G. Buda, A. Lazzaro, P. Gobbi, C. Stelitano, F. Morabito, G. Quarta, M. Brugiatelli (2008)
Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year follow-up studyHaematologica, 93
Jianfei Huang, Jie Liang, Q. Tang, Zhong-Can Wang, Leru Chen, Jin Zhu, Zhenqing Feng (2011)
An active murine–human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumorsApplied Microbiology and Biotechnology, 91
D. Gold, T. Cardillo, Y. Vardi, R. Blumenthal (1997)
Radioimmunotherapy of experimental pancreatic cancer with 131I‐labeled monoclonal antibody PAM4International Journal of Cancer, 71
P. Riva, A. Arista, C. Sturiale, V. Tison, S. Lazzari, G. Franceschi, A. Spinelli, M. Casi, G. Sarti, F. Campori, N. Riva (2007)
Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodiesCell Biophysics, 24-25
J. Ventimiglia, C. Wikstrand, L. Ostrowski, M. Bourdon, V. Lightner, D. Bigner (1992)
Tenascin expression in human glioma cell lines and normal tissuesJournal of Neuroimmunology, 36
(2010)
Author manuscript, published in "Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2009;50 (12):2033-41"
M. Zalutsky, ROBIN Moseley, J. Benjamin, E. Colapinto, G. Fuller, H. Coakham, D. Bigner (1990)
Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration.Cancer research, 50 13
Jing Xu, Z. Shen, Xinguo Chen, Qing Zhang, H. Bian, P. Zhu, Hui Xu, Fei Song, Xiang-min Yang, Lisyany Mi, Qing-chuan Zhao, R. Tian, Q. Feng, Si-he Zhang, Yu Li, Jian-Li Jiang, Ling Li, Xiaoling Yu, Zheng Zhang, Zhi-Nan Chen (2007)
A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantationHepatology, 45
J. Leonard, M. Coleman, L. Kostakoglu, A. Chadburn, E. Cesarman, R. Furman, M. Schuster, R. Niesvizky, D. Muss, J. Fiore, S. Kroll, G. Tidmarsh, S. Vallabhajosula, S. Goldsmith (2005)
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 24
D. Colcher, G. Pavlínková, G. Beresford, B. Booth, A. Choudhury, S. Batra (1998)
Pharmacokinetics and biodistribution of genetically-engineered antibodies.The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology, 42 4
R. Patchell (1991)
Brain metastases.Neurologic clinics, 9 4
H. Nordenstedt, D. White, H. El‐Serag (2010)
The changing pattern of epidemiology in hepatocellular carcinoma.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 42 Suppl 3
P. Burtin, G. Chavanel, J. Hendrick, N. Frenoy (1986)
Antigenic variants of the nonspecific cross-reacting antigen (NCA).Journal of immunology, 137 3
A. Jungbluth, E. Stockert, H. Huang, V. Collins, K. Coplan, K. Iversen, D. Kolb, T. Johns, A. Scott, W. Gullick, G. Ritter, L. Cohen, M. Scanlan, Webster Cavanee, L. Old (2003)
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptorProceedings of the National Academy of Sciences of the United States of America, 100
U. Murthy, A. Basu, U. Rodeck, M. Herlyn, A. Ross, M. Das (1987)
Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide.Archives of biochemistry and biophysics, 252 2
E. Perez, E. Romond, V. Suman, Jong-Hyeon Jeong, G. Sledge, C. Geyer, S. Martino, P. Rastogi, J. Gralow, S. Swain, E. Winer, G. Colón-Otero, N. Davidson, E. Mamounas, J. Zujewski, N. Wolmark (2014)
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 33
R. Blumenthal, R. Sharkey, D. Snyder, H. Hansen, D. Goldenberg (1988)
Reduction of radioantibody-induced myelotoxicity in hamsters by recombinant interleukin-1.Cancer research, 48 19
F. Primus, W. Kuhns, D. Goldenberg (1983)
Immunological heterogeneity of carcinoembryonic antigen: immunohistochemical detection of carcinoembryonic antigen determinants in colonic tumors with monoclonal antibodies.Cancer research, 43 2
A. Pini, F. Viti, A. Santucci, B. Carnemolla, L. Zardi, P. Neri, D. Neri (1998)
Design and Use of a Phage Display LibraryThe Journal of Biological Chemistry, 273
P. Chinn, Ron Morena, D. Santoro, T. Kazules, S. Kashmiri, J. Schlom, N. Hanna, G. Braslawsky (2006)
Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.Cancer biotherapy & radiopharmaceuticals, 21 2
I. Zanten‐Przybysz, C. Molthoff, J. Roos, R. Verheijen, A. Hof, M. Buist, H. Prinssen, W. Hollander, P. Kenemans (2001)
Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p.International Journal of Cancer, 92
Olivia Taylor, Joshua Brzozowski, K. Skelding (2019)
Glioblastoma Multiforme: An Overview of Emerging Therapeutic TargetsFrontiers in Oncology, 9
C. Bodet-Milin, L. Ferrer, A. Pallardy, T. Eugène, A. Rauscher, A. Faivre-Chauvet, J. Barbet, F. Kraeber-Bodéré (2013)
Radioimmunotherapy of B-Cell Non-Hodgkin’s LymphomaFrontiers in Oncology, 3
McKinsey Goodenberger, R. Jenkins (2012)
Genetics of adult glioma.Cancer genetics, 205 12
P. Castellani, G. Viale, A. Dorcaratto, G. Nicolò, J. Kaczmarek, G. Querzé, L. Zardi (1994)
The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesisInternational Journal of Cancer, 59
Zheng Zhang, H. Bian, Q. Feng, Lisyany Mi, Tingshu Mo, An'ren Kuang, Tian-zhi Tan, Yunchun Li, Wu-sheng Lu, Yang Zhang, Min Zhang, R. Tian, Zhi-Nan Chen, P. Zhu (2006)
Biodistribution and localization of iodine-131 labeled metuximab in patients with hepatocellular carcinomaCancer Biology & Therapy, 5
M. Buist, P. Kenemans, W. Hollander, J. Vermorken, C. Molthoff, C. Burger, T. Helmerhorst, J. Baak, J. Roos (1993)
Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients.Cancer research, 53 22
M. Kaminski, K. Zasadny, I. Francis, Adam Milik, C. Ross, Scott Moon, Shelley Crawford, J. Burgess, N. Petry, G. Butchko, S. Glenn, R. Wahl (1993)
Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.The New England journal of medicine, 329 7
A. Epenetos, A. Munro, S. Stewart, R. Rampling, H. Lambert, C. McKenzie, P. Soutter, A. Rahemtulla, G. Hooker, G. Sivolapenko (1987)
Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 5 12
D. Slavin-Chiorini, D. Slavin-Chiorini, S. Kashmiri, J. Schlom, B. Calvo, Lee Shu, M. Schott, D. Milenic, P. Snoy, J. Carrasquillo, Kerr Anderson, P. Hand (1995)
Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.Cancer research, 55 23 Suppl
(1980)
Characterization of a human lymphocyte-B-specific antigen
R. Lu, Yu-Chyi Hwang, I. Liu, Chi-Chiu Lee, Han-zen Tsai, Hsin-Jung Li, Han‐Chung Wu (2020)
Development of therapeutic antibodies for the treatment of diseasesJournal of Biomedical Science, 27
Y. Lee, D. Bullard, M. Zalutsky, R. Coleman, C. Wikstrand, H. Friedman, E. Colapinto, D. Bigner (1988)
Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.Cancer research, 48 3
G. Virotta, G. Poli, A. Bettini, C. Bianchi, L. Giovannoni, A. Gerali, A. Quadri, C. Tondini, A. Bruno (2012)
Radioimmunotherapy with 131I-L19SIP (Radretumab) in metastatic solid tumors: Preliminary resultsThe Journal of Nuclear Medicine, 53
B. Link, P. Martin, M. Kaminski, S. Goldsmith, M. Coleman, J. Leonard (2010)
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 18
D. Buchsbaum, R. Wahl, D. Normolle, M. Kaminski (1992)
Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.Cancer research, 52 23
Alan Epstein, Feng-Ming Chen, Clive Taylor (1988)
A novel method for the detection of necrotic lesions in human cancers.Cancer research, 48 20
E. El-Emir, Jason Dearling, A. Huhalov, Mathew Robson, G. Boxer, Dario Neri, G.A.M.S. Dongen, E. Trachsel, R. Begent, Rbab Pedley (2007)
Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour modelsBritish Journal of Cancer, 96
Rbab Pedley, J. Boden, R. Bodén, R. Dale, R. Begent (1993)
Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.British Journal of Cancer, 68
D. Goldenberg, T. Wlodkowski, R. Sharkey, E. Silberstein, A. Serafini, I. Garty, R. Heertum, E. Higginbotham-Ford, J. Kotler, N. Balasubramanian (1993)
Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 34 1
H. Sung, J. Ferlay, R. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray (2021)
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 71
O. Press, J. Unger, L. Rimsza, J. Friedberg, M. LeBlanc, M. Czuczman, M. Kaminski, R. Braziel, D. Maloney, B. Cheson, T. Miller, R. Fisher (2011)
A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's LymphomaBlood, 118
Xuanmin He, G. Archer, C. Wikstrand, S. Morrison, M. Zalutsky, D. Bigner, S. Batra (1994)
Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascinJournal of Neuroimmunology, 52
R. Perera, R. Zoncu, T. Johns, M. Pypaert, F. Lee, I. Mellman, L. Old, D. Toomre, A. Scott (2007)
Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.Neoplasia, 9 12
(2011)
Cancer radioimmunotherapy. Immunotherapy 3:349–370
Samuel Yeh, Steven Larson, L. Burch, B. Kushner, M. LaQuaglia, Ronald Finn, Nai-Kong Cheung (1991)
Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 32 5
H Shepard, Gail Phillips, Christopher Thanos, M. Feldmann (2017)
Developments in therapy with monoclonal antibodies and related proteinsClinical Medicine, 17
M. Muto, N. Finkler, A. Kassis, A. Howes, L. Anderson, Ching Lau, V. Zurawski, K. Weadock, Tumeh Ss, P. Lavin, R. Knapp (1992)
Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125.Gynecologic oncology, 45 3
K. Kramer, B. Kushner, S. Modak, N. Pandit-Taskar, P. Smith-Jones, P. Zanzonico, J. Humm, Hong Xu, S. Wolden, M. Souweidane, S. Larson, N. Cheung (2010)
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastomaJournal of Neuro-Oncology, 97
R. Sharkey, D. Goldenberg, S. Murthy, H. Pinsky, R. Vagg, D. Pawlyk, J. Siegel, G. Wong, P. Gascón, D. Izon, M. Vezza, K. Burger, L. Swayne, C. Pinsky, H. Hansen (1993)
Clinical evaluation of tumor targeting with a high‐affinity, anticarcinoembryonic‐antigen‐specific, murine monoclonal antibody, MN‐14Cancer, 71
J. Greiner, P. Hand, P. Noguchi, P. Fisher, S. Pestka, J. Schlom (1984)
Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment.Cancer research, 44 8
N. Cheung, I. Cheung, B. Kushner, I. Ostrovnaya, Elizabeth Chamberlain, K. Kramer, S. Modak (2012)
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 26
C. Molthoff, M. Buist, P. Kenemans, H. Pinedo, E. Boven (1992)
Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 33 11
D Lane, K Eagle, R Begent, L Hopestone, A Green, J Casey (1994)
Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labeled antibody to carcinoembryonic antigen - Phase I/II study with comparative biodistribution of intact and F(ab')(2) antibodiesBr J Cancer, 70
M. Trzpis, P. McLaughlin, L. Leij, M. Harmsen (2007)
Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule.The American journal of pathology, 171 2
Like Yu, D. Ju, Wenping Chen, Tian Li, Zhaoqiang Xu, Changying Jiang, Shaoliang Chen, Q. Tao, D. Ye, P. Hu, L. Khawli, C. Taylor, A. Epstein (2006)
131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer.Cancer biotherapy & radiopharmaceuticals, 21 1
Frances Benham, M. Povey, Harry Harris (1978)
Placental-like alkaline phosphatase in malignant and benign ovarian tumors.Clinica chimica acta; international journal of clinical chemistry, 86 2
Maneesh Jain, Suprit Gupta, S. Kaur, M. Ponnusamy, S. Batra (2013)
Emerging trends for radioimmunotherapy in solid tumors.Cancer biotherapy & radiopharmaceuticals, 28 9
S. Welt, G. Ritter, Clarence Williams, L. Cohen, M. John, A. Jungbluth, Elizabeth Richards, L. Old, N. Kemeny (2003)
Phase I study of anticolon cancer humanized antibody A33.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 4
O. Press, J. Unger, R. Braziel, D. Maloney, T. Miller, M. LeBlanc, E. Gaynor, S. Rivkin, R. Fisher (2003)
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.Blood, 102 5
M. Kaminski, J. Estes, K. Zasadny, I. Francis, C. Ross, M. Tuck, D. Regan, S. Fisher, Jeanne Gutierrez, S. Kroll, R. Stagg, G. Tidmarsh, R. Wahl (2000)
Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.Blood, 96 4
A. Epenetos, D. Carr, P. Johnson, W. Bodmer, J. Lavender (1986)
Antibody-guided radiolocalisation of tumours in patients with testicular or ovarian cancer using two radioiodinated monoclonal antibodies to placental alkaline phosphatase.The British journal of radiology, 59 698
I. Cokgor, G. Akabani, C. Kuan, H. Friedman, A. Friedman, R. Coleman, R. McLendon, S. Bigner, Xiaoguang Zhao, Ana Garcia-Turner, C. Pegram, C. Wikstrand, T. Shafman, J. Herndon, J. Provenzale, M. Zalutsky, D. Bigner (2000)
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 22
D Goldenberg, F Deland, S Bennett, F Primus, M Nelson, R Flanigan (1983)
Radioimmunodetection of prostatic-cancer—invivo use of radioactive antibodies against prostatic acid-phosphatase for diagnosis and detection of prostatic-cancer by nuclear imagingJAMA J Am Med Assoc, 250
P. Hutzell, S. Kashmiri, D. Colcher, F. Primus, P. Hand, M. Roselli, M. Finch, G. Yarranton, M. Bodmer, N. Whittle (1991)
Generation and characterization of a recombinant/chimeric B72.3 (human gamma 1).Cancer research, 51 1
S. Larson, K. Pentlow, N. Volkow, A. Wolf, R. Finn, R. Lambrecht, M. Graham, Gene Resta, B. Bendriem, F. Daghighian, S. Yeh, G. Wang, N. Cheung (1992)
PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 33 11
M. Russeva, G. Adams (2004)
Radioimmunotherapy with engineered antibodiesExpert Opinion on Biological Therapy, 4
W. Strohl (2017)
Current progress in innovative engineered antibodiesProtein & Cell, 9
Jascha-N Rybak, E. Trachsel, Jörg Scheuermann, D. Neri (2007)
Ligand‐Based Vascular Targeting of DiseaseChemMedChem, 2
H. El‐Serag, K. Rudolph (2007)
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.Gastroenterology, 132 7
G. Lombardi, A. Stefano, P. Farina, V. Zagonel, E. Tabouret (2014)
Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.Cancer treatment reviews, 40 8
E. Weledji, J. Assob (2014)
The ubiquitous neural cell adhesion molecule (N-CAM)Annals of Medicine and Surgery, 3
D. Neri, R. Bicknell (2005)
Tumour vascular targetingNature Reviews Cancer, 5
M. Herlyn, Z. Steplewski, D. Herlyn, H. Koprowski (1979)
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.Proceedings of the National Academy of Sciences of the United States of America, 76 3
M. Morris, J. Bono, K. Chi, K. Fizazi, K. Herrmann, K. Rahbar, S. Tagawa, L. Nordquist, N. Vaishampayan, G. El-Haddad, Chandler Park, T. Beer, Wendy Pérez-Contreras, M. Desilvio, E. Kpamegan, G. Gericke, R. Messmann, B. Krause, A. Sartor (2021)
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).Journal of Clinical Oncology, 39
P. Li, S. Vecchio, R. Fonti, M. Carriero, M. Potena, G. Botti, S. Miotti, S. Lastoria, S. Ménard, M. Colnaghi, M. Salvatore (1996)
Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 37 4
J. Shively, J. Beatty (1985)
CEA-related antigens: molecular biology and clinical significance.Critical reviews in oncology/hematology, 2 4
J. Ferlay, M. Colombet, I. Soerjomataram, D. Parkin, M. Piñeros, A. Znaor, F. Bray (2021)
Cancer statistics for the year 2020: An overviewInternational Journal of Cancer, 149
Maneesh Jain, G. Venkatraman, S. Batra (2007)
Optimization of Radioimmunotherapy of Solid Tumors: Biological Impediments and Their ModulationClinical Cancer Research, 13
C. Sahlmann, K. Homayounfar, M. Niessner, J. Dyczkowski, L. Conradi, F. Braulke, B. Meller, T. Beissbarth, M. Ghadimi, Johannes Meller, D. Goldenberg, T. Liersch (2016)
Repeated adjuvant anti‐CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long‐term efficacy results of a prospective phase 2 studyCancer, 123
S. Morrison (1985)
Transfectomas provide novel chimeric antibodies.Science, 229 4719
D. Reardon, G. Akabani, R. Coleman, A. Friedman, H. Friedman, J. Herndon, I. Cokgor, R. McLendon, C. Pegram, J. Provenzale, J. Quinn, J. Rich, Lorna Regalado, J. Sampson, T. Shafman, C. Wikstrand, T. Wong, Xiaoguang Zhao, M. Zalutsky, D. Bigner (2002)
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 5
C. Sunderland, J. Davies, G. Stirrat (1984)
Immunohistology of normal and ovarian cancer tissue with a monoclonal antibody to placental alkaline phosphatase.Cancer research, 44 10
A. Goldman, G. Vivian, I. Gordon, J. Pritchard, J. Kemshead (1984)
Immunolocalization of neuroblastoma using radiolabeled monoclonal antibody UJ13A.The Journal of pediatrics, 105 2
R. Verheijen, L. Massuger, B. Benigno, A. Epenetos, A. Lopes, J. Soper, J. Markowska, R. Vyzula, T. Jobling, G. Stamp, G. Spiegel, D. Thurston, Theo Falke, J. Lambert, M. Seiden (2006)
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 4
Zhi-Nan Chen, Lisyany Mi, Jing Xu, Fei Song, Qing Zhang, Zheng Zhang, J. Xing, H. Bian, Jian-Li Jiang, Xian-hui Wang, P. Shang, A. Qian, Si-he Zhang, Ling Li, Y. Li, Q. Feng, Xiaoling Yu, Yuan Feng, Xiang-min Yang, R. Tian, Zhenpeng Wu, Nan Leng, Ting-Shu Mo, A. Kuang, Tian-zhi Tan, Yun-chun Li, De-Rong Liang, Wu-sheng Lu, J. Miao, Guo Xu, Zhi-hui Zhang, K. Nan, Jun Han, Qing-guang Liu, Hong-xin Zhang, P. Zhu (2006)
Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.International journal of radiation oncology, biology, physics, 65 2
Carla Moltoff, H. Prinssen, P. Kenemans, A. Hof, W. Hollander, R. Verheijen (1997)
Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I studyCancer, 80
Jianfei Huang, Q. Tang, Changjun Wang, Huixin Yu, Zhenqing Feng, Jin Zhu (2015)
Molecularly Targeted Therapy of Human Hepatocellular Carcinoma Xenografts with Radio-iodinated Anti-VEGFR2 Murine-Human Chimeric FabScientific Reports, 5
H. Bian, Jia-sheng Zheng, Gang Nan, Rui Li, Changsheng Chen, Cai-Xia Hu, Yang Zhang, Bin Sun, Xi-Long Wang, S. Cui, Jiao Wu, Jing Xu, D. Wei, Xiaoyong Zhang, Haichun Liu, Wuwei Yang, Yong Ding, Jing Li, Zhi-Nan Chen (2014)
Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation.Journal of the National Cancer Institute, 106 9
L. Borsi, E. Balza, M. Bestagno, P. Castellani, B. Carnemolla, A. Biró, A. Leprini, J. Sepúlveda, O. Burrone, D. Neri, L. Zardi (2002)
Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectinInternational Journal of Cancer, 102
W. Shapiro, S. Carpenter, K. Roberts, J. Shan (2006)
131I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic gliomaExpert Opinion on Biological Therapy, 6
R. Sharkey, D. Goldenberg, H. Goldenberg, R. Lee, C. Ballance, D. Pawlyk, D. Varga, H. Hansen (1990)
Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic, and targeting properties in humans.Cancer research, 50 9
S. Tagawa, H. Beltran, S. Vallabhajosula, S. Goldsmith, J. Osborne, D. Matulich, K. Petrillo, S. Parmar, D. Nanus, N. Bander (2010)
Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancerCancer, 116
D. Macey, E. Grant, L. Kasi, M. Rosenblum, H. Zhang, R. Katz, P. Rieger, D. Lebherz, M. South, J. Greiner, J. Schlom, D. Podoloff, J. Murray (1997)
Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.Clinical cancer research : an official journal of the American Association for Cancer Research, 3 9
Lee Sun, Peter CURTISt, Eva RAKOWICZ-SZULCZYNSKAt, John Ghrayeb, Nancy, Chang, L. Sherie, Morrisonii, Hilary KOPROWSKIt (1987)
Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A.Proceedings of the National Academy of Sciences of the United States of America, 84 1
A. Molinolo, J. Simpson, A. Thor, J. Schlom (1990)
Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue.Cancer research, 50 4
D. Milenic, T. Yokota, D. Filpula, M. Finkelman, S. Dodd, J. Wood, M. Whitlow, P. Snoy, J. Schlom (1991)
Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.Cancer research, 51 23 Pt 1
M. Sadaghiani, S. Sheikhbahaei, R. Werner, K. Pienta, M. Pomper, L. Solnes, M. Gorin, Nae-Yuh Wang, S. Rowe (2021)
A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.European urology
J. Marken, G. Schieven, I. Hellstrom, K. Hellström, A. Aruffo (1992)
Cloning and expression of the tumor-associated antigen L6.Proceedings of the National Academy of Sciences of the United States of America, 89
J. Emrich, L. Brady, T. Quang, R. Class, C. Miyamoto, P. Black, U. Rodeck (2002)
Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patientsAmerican Journal of Clinical Oncology, 25
G. Chong, F. Lee, W. Hopkins, N. Tebbutt, J. Cebon, A. Mountain, B. Chappell, A. Papenfuss, P. Schleyer, R. Murphy, VeronikaWirth, F. Smyth, Nicole Potasz, A. Poon, I. Davis, T. Saunder, G. O'Keefe, A. Burgess, E. Hoffman, L. Old, A. Scott (2005)
Phase I Trial of 131 I-huA 33 in Patientswith Advanced Colorectal Carcinoma
M. Hens, G. Vaidyanathan, P. Welsh, M. Zalutsky (2009)
Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.Nuclear medicine and biology, 36 2
D. Green, O. Press (2017)
Whither Radioimmunotherapy: To Be or Not To Be?Cancer research, 77 9
M. Keyaerts, C. Xavier, Johannes Heemskerk, N. Devoogdt, H. Everaert, Chloé Ackaert, M. Vanhoeij, F. Duhoux, T. Gevaert, P. Simon, D. Schallier, C. Fontaine, I. Vaneycken, C. Vanhove, J. Grève, J. Lamote, V. Caveliers, T. Lahoutte (2016)
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast CarcinomaThe Journal of Nuclear Medicine, 57
C. Qu, C. Qu, Yong Li, Yan Song, Yan Song, S. Rizvi, C. Raja, David Zhang, J. Samra, J. Samra, Ross Smith, Ross Smith, A. Perkins, C. Apostolidis, B. Allen, B. Allen (2004)
MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugateBritish Journal of Cancer, 91
(1989)
Tumour necrosis treatment of me-180 human cervical-carcinoma model with i-131-labeled TNT-1 monoclonal-antibody
'. D.M.Lane, '. K.F.Eagle, '. R.H.J.Begent, '. L.D.Hope-Stone, J. A., '. Green, L. J., '. Casey, A. P., '. Keep, '. A.M.B.Kelly, J. Ledermann, M. Glaser, W. A.J., Hilson (2007)
carcinoembryonic antigen: phase I/Il study with comparative biodistribution of intact and F(ab') antibodies
L. Brady, C. Miyamoto, D. Woo, M. Rackover, J. Emrich, H. Bender, S. Dadparvar, Z. Steplewski, H. Koprowski, P. Black, B. Lazzaro, Somnath Nair, T. McCormack, Joseph Nieves, M. Morabito, J. Eshleman (1992)
Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial.International journal of radiation oncology, biology, physics, 22 1
R Sharkey, C Mottahennessy, D Pawlyk, J Siegel, D Goldenberg (1990)
Biodistribution and radiation-dose estimates for yttrium-labeled and iodine-labeled monoclonal-antibody IGG and fragments in nude-mice bearing human colonic tumour xenograftsCancer Res, 50
Zhenyi An, O. Aksoy, Tina Zheng, Q. Fan, W. Weiss (2017)
Epidermal growth factor receptor (EGFR) and EGFRvIII in glioblastoma (GBM): signaling pathways and targeted therapiesOncogene, 37
K. Moseley, A. Battaile, R. Knapp, H. Haisma (1988)
Localization of radiolabelled F(ab′)2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenograftsInternational Journal of Cancer, 42
B. Tijink, D. Neri, C. Leemans, M. Budde, L. Dinkelborg, M. Walsum, L. Zardi, G. Dongen (2006)
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 47 7
Shaoliang Chen, Like Yu, Changying Jiang, Yan Zhao, Da Sun, Shenyu Li, G. Liao, Yangchun Chen, Q. Fu, Q. Tao, D. Ye, P. Hu, L. Khawli, C. Taylor, A. Epstein, D. Ju (2005)
Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 7
O. Press, J. Unger, L. Rimsza, J. Friedberg, M. LeBlanc, M. Czuczman, M. Kaminski, R. Braziel, C. Spier, A. Gopal, D. Maloney, B. Cheson, S. Dakhil, T. Miller, R. Fisher (2013)
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 3
Qing He, Wu-sheng Lu, Yang Liu, Y. Guan, A. Kuang (2013)
131 I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma
J. Winter, Laura Tang, D. Klimstra, M. Brennan, J. Brody, F. Rocha, X. Jia, L. Qin, M. D'Angelica, R. DeMatteo, Y. Fong, W. Jarnagin, E. O’Reilly, P. Allen (2012)
A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as BiomarkersPLoS ONE, 7
D. Slavin-Chiorini, P. Hand, S. Kashmiri, B. Calvo, S. Zaremba, J. Schlom (1993)
Biologic properties of a Ch2 domain‐deleted recombinant immunoglobulinInternational Journal of Cancer, 53
O. Press, Janet Howell-Clark, S. Anderson, I. Bernstein (1994)
Retention of B-cell-specific monoclonal antibodies by human lymphoma cells.Blood, 83 5
R. Finn (2010)
Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?Clinical Cancer Research, 16
J. Vose, R. Wahl, M. Saleh, A. Rohatiner, S. Knox, J. Radford, A. Zelenetz, G. Tidmarsh, R. Stagg, M. Kaminski (2000)
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 6
S. Miotti, S. Canevari, S. Ménard, D. Mezzanzanica, Giuliana Porro, S. Pupa, M. Regazzoni, E. Tagliabue, M. Colnaghi (1987)
Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificityInternational Journal of Cancer, 39
S. Denardo, L. O'Grady, C. Richman, D. Goldstein, R. O'donnell, D. DeNardo, L. Kroger, K. Lamborn, K. Hellström, I. Hellstrom, G. Denardo (1997)
Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.Anticancer research, 17 3B
G. Ritter, L. Cohen, E. Nice, B. Catimel, A. Burgess, R. Moritz, H. Ji, J. Heath, S. White, S. Welt, L. Old, R. Simpson (1997)
Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium.Biochemical and biophysical research communications, 236 3
M. Zalutsky, ROBIN Moseley, Hugh Coakham, R. Coleman, D. Bigner (1989)
Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.Cancer research, 49 10
D. Jones, L. Lashford, C. Dicks-Mireaux, J. Kemshead (1987)
Comparison of pharmacokinetics of radiolabeled monoclonal antibody UJ13A in patients and animal models.NCI monographs : a publication of the National Cancer Institute, 3
Ralf Wilkowski, Maria Wolf, V. Heinemann (2008)
Primary advanced unresectable pancreatic cancer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 177
K. Kramer, J. Humm, M. Souweidane, P. Zanzonico, I. Dunkel, W. Gerald, Y. Khakoo, S. Yeh, H. Yeung, R. Finn, S. Wolden, S. Larson, N. Cheung (2007)
Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 34
G. Goodman, I. Hellström, L. Brodzinsky, C. Nicaise, B. Kulander, D. Hummel, K. Hellström (1990)
Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 6
M. Bourdon, T. Matthews, S. Pizzo, D. Bigner (1985)
Immunochemical and biochemical characterization of a glioma‐associated extracellular matrix glycoproteinJournal of Cellular Biochemistry, 28
James Murray, D. Macey, Edward Grant, M. Rosenblum, L. Kasi, Huazhong Zhang, R. Katz, P. Rieger, D. Lebherz, V. Bhadkamkar, J. Greiner, J. Schlom, D. Podoloff (1995)
Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment.Cancer research, 55 23 Suppl
F. Crippa, G. Buraggi, E. Re, M. Gasparini, E. Seregni, S. Canevari, M. Gadina, M. Presti, A. Marini, E. Seccamani (1991)
Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody.European journal of cancer, 27 6
P. Mukherjee, C. Madsen, Amelia Ginardi, T. Tinder, †Fred Jacobs, †Joanne Parker, †‡Babita Agrawal, †B. Longenecker, S. Gendler (2003)
Mucin 1-Specific Immunotherapy in a Mouse Model of Spontaneous Breast CancerJournal of Immunotherapy, 26
H. Haisma, K. Moseley, A. Battaile, T. Griffiths, R. Knapp (1988)
Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors.American journal of obstetrics and gynecology, 159 4
R Sharkey, D Goldenberg (2011)
Cancer radioimmunotherapyImmunotherapy, 3
Rosalia Veggian, Silvano Fasolato, S. Ménard, D. Minucci, P. Pizzetti, M. Regazzoni, E. Tagliabue, M. Colnaghi (1989)
Immunohistochemical Reactivity of a Monoclonal Antibody Prepared against Human Ovarian Carcinoma on Normal and Pathological Female Genital TissuesTumori Journal, 75
B. Cheson (2003)
Radioimmunotherapy of non-Hodgkin lymphomas.Blood, 101 2
T. Cardillo, Zhiliang Ying, David Gold (2001)
Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 10
J. Greiner, C. Ullmann, C. Nieroda, C. Qi, D. Eggensperger, S. Shimada, S. Steinberg, J. Schlom (1993)
Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.Cancer research, 53 3
P. Gold, S. Freedman (1965)
SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEMThe Journal of Experimental Medicine, 122
A. Kassis (2008)
Therapeutic radionuclides: biophysical and radiobiologic principles.Seminars in nuclear medicine, 38 5
R Meredith, M Khazaeli, D Macey, W Grizzle, M Mayo, J Schlom (1999)
Phase II study of interferon-enhanced I-131-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancerClin Cancer Res, 5
G. Nowakowski, T. Witzig (2006)
Radioimmunotherapy for B-cell non-Hodgkin lymphoma.Clinical advances in hematology & oncology : H&O, 4 3
H. Koprowski, Z. Steplewski, K. Mitchell, M. Herlyn, D. Herlyn, Peter Fuhrer (1979)
Colorectal carcinoma antigens detected by hybridoma antibodiesSomatic Cell Genetics, 5
J. Carrasquillo, P. Sugarbaker, D. Colcher, J. Reynolds, J. Esteban, G. Bryant, P. Perentesis, K. Yokoyama, M. Rotman, J. Schlom (1988)
Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72.3 monoclonal antibody.Radiology, 167 1
U. Haberkorn, M. Eder, K. Kopka, J. Babich, M. Eisenhut (2016)
New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and TherapyClinical Cancer Research, 22
C. Brown, R. Modzelewski, Candace Johnson, M. Wong (2000)
A Novel Approach for the Identification of Unique Tumor Vasculature Binding Peptides Using an E. coli Peptide Display LibraryAnnals of Surgical Oncology, 7
Jianfei Huang, Xia-ling Zhang, Q. Tang, Feng Zhang, Yu-hua Li, Zhenqing Feng, Jin Zhu (2011)
Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinomaJournal of Clinical Pathology, 64
A. Siri, B. Carnemolla, M. Saginati, A. Leprini, G. Casari, F. Baralle, L. Zardi (1991)
Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies.Nucleic acids research, 19 3
R Finn (2010)
Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? (vol 16, pg 390, 2010)Clin Cancer Res, 16
M. Mahé, P. Fumoleau, M. Fabbro, J. Guastalla, P. Faurous, P. Chauvot, Lucienne Chetanoud, J. Classe, P. Rouanet, J. Chatal (1999)
A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 10 Suppl
G. Hajjar, R. Sharkey, J. Burton, Chu-hui Zhang, Dion Yeldell, A. Matthies, A. Alavi, M. Losman, Arnold Brenner, D. Goldenberg (2002)
Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.Clinical colorectal cancer, 2 1
Linna Li, T. Quang, E. Gracely, J. Kim, J. Emrich, T. Yaeger, J. Jenrette, Steven Cohen, P. Black, L. Brady (2010)
A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.Journal of neurosurgery, 113 2
M Juweid, R Sharkey, L Swayne, T Behr, R Dunn, D Goldenberg (1996)
Radioimmunotherapy in patients with CEA-producing cancers and small-volume disease using I-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')(2)J Nucl Med, 37
S. Schold, M. Zalutsky, R. Coleman, M. Glantz, A. Friedman, R. Jaszczak, S. Bigner, D. Bigner (1993)
Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.Investigative radiology, 28 6
Alia Hdeib, A. Sloan (2012)
Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas.Future oncology, 8 6
W. Shapiro, D. Gupta, A. Mahapatra, S. Gopal, K. Judy, S. Patel, J. Shan (2011)
Open-label, dose confirmation study of interstitial 131I-chTNT-1/b mab for the treatment of glioblastoma multiforme (GBM) at first relapse: Interim results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
M. Kaminski, A. Zelenetz, O. Press, M. Saleh, J. Leonard, L. Fehrenbacher, T. Lister, R. Stagg, G. Tidmarsh, Stew Kroll, R. Wahl, S. Knox, J. Vose (2001)
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 19
B. Carnemolla, E. Balza, A. Siri, L. Zardi, M. Nicotra, A. Bigotti, P. Natali (1989)
A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursorsThe Journal of Cell Biology, 108
F. Primus, K. Newell, A. Blue, D. Goldenberg (1983)
Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies.Cancer research, 43 2
S Welt, C DivgI, N Kemeny, R Finn, A Scott, M Graham (1994)
Phase I/II study of iodine 131-LABELED monoclonal-antibody A33 in patients with advanced colon-canceRJ Clin Oncol, 12
Qing He, Wu-sheng Lu, Yang Liu, Y. Guan, A. Kuang (2013)
131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma.World journal of gastroenterology, 19 47
M. Jong, C. Pulitano, D. Ribero, Jennifer Strub, G. Mentha, R. Schulick, M. Choti, L. Aldrighetti, L. Capussotti, T. Pawlik (2009)
Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 1669 PatientsAnnals of Surgery, 250
N. Whittle, J. Adair, C. Lloyd, L. Jenkins, J. Devine, J. Schlom, A. Raubitschek, D. Colcher, M. Bodmer (1987)
Expression in COS cells of a mouse-human chimaeric B72.3 antibody.Protein engineering, 1 6
T. Mulligan, J. Carrasquillo, Y. Chung, D. Milenic, J. Schlom, I. Feuerstein, C. Paik, P. Perentesis, J. Reynolds, Curt Ga (1995)
Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, 1 12
J. Heath, S. White, Cameron Johnstone, B. Catimel, R. Simpson, R. Moritz, G. Tu, H. Ji, R. Whitehead, L. Groenen, A. Scott, G. Ritter, L. Cohen, S. Welt, L. Old, E. Nice, A. Burgess (1997)
The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily.Proceedings of the National Academy of Sciences of the United States of America, 94 2
D. Einfeld, J. Brown, Mary Valentine, Edward Clark, Jeffrey Ledbetter (1988)
Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.The EMBO Journal, 7
B. Altunay, A. Morgenroth, M. Beheshti, A. Vogg, N. Wong, H. Ting, H. Biersack, E. Stickeler, F. Mottaghy (2020)
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 48
R. Meredith, M. Khazaeli, W. Plott, S. Spencer, R. Wheeler, Luther Brady, D. Woo, A. Lobuglio (1995)
Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 36 12
A. Epenetos, J. Shepherd, K. Britton, S. Mather, J. Taylor‐Papadimitriou, M. Granowska, H. Durbin, C. Nimmon, L. Hawkins, J. Malpas, W. Bodmer (1985)
123I radioiodinated antibody imaging of occult ovarian cancerCancer, 55
Sunil Patel, W. Shapiro, D. Laske, R. Jensen, A. Asher, B. Wessels, S. Carpenter, J. Shan (2005)
Safety and Feasibility of Convection-enhanced Delivery of Cotara for the Treatment of Malignant Glioma: Initial Experience in 51 PatientsNeurosurgery, 56
Shaoliang Chen, Bei-lei Li, H. Xie, Li Xu, Guangjun Niu, Kuisheng Fan, Q. Fan (2004)
Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma.Cancer biotherapy & radiopharmaceuticals, 19 5
(1995)
In-vitro and in-vivo activities of a doxorubicin prodrug in combination with monoclonal-antibody betalactamase conjugates
S. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas, D. Podoloff, M. Goris (2005)
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 4
B. Wessels, R. Rogus (1984)
Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.Medical physics, 11 5
(2002)
Incidence of brain Metastases in a cohort of patients with breast, colon, kidney, and lung cancer, and melanoma
Heinrich Göitlinger, I. Funke, Judith Johnson, J. Gokel, G. Riethmüller (1986)
The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodiesInternational Journal of Cancer, 38
B. Nordlinger, H. Sorbye, B. Glimelius, G. Poston, P. Schlag, P. Rougier, W. Bechstein, J. Primrose, E. Walpole, M. Finch-Jones, D. Jaeck, D. Mirza, R. Parks, M. Mauer, E. Tanis, E. Cutsem, W. Scheithauer, T. Gruenberger (2013)
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.The Lancet. Oncology, 14 12
Qing Zhang, Jun Zhou, Xiao-Ming Ku, Xinguo Chen, Li Zhang, Jing Xu, Guangsheng Chen, Qin Li, F. Qian, R. Tian, Ning Wen, Zhi-Nan Chen (2007)
Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinomaEuropean Journal of Cancer Prevention, 16
F. Buchegger, A. Pèlegrin, B. Delaloye, A. Bischof-Delaloye, J. Mach (1990)
Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 31 6
T. Liersch, Johannes Meller, B. Kulle, T. Behr, P. Markus, C. Langer, B. Ghadimi, W. Wegener, J. Kovacs, I. Horak, H. Becker, D. Goldenberg (2005)
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 27
J. Emrich, L. Brady, T. Quang, R. Class, C. Miyamoto, P. Black, U. Rodeck (2002)
Radioiodinated (I-125) Monoclonal Antibody 425 in the Treatment of High Grade Glioma Patients: Ten-Year Synopsis of a Novel TreatmentAmerican Journal of Clinical Oncology, 25
D. Colcher, P. Hand, M. Nuti, J. Schlom (1981)
A spectrum of monoclonal antibodies reactive with human mammary tumor cells.Proceedings of the National Academy of Sciences of the United States of America, 78 5
C. Divgi, A. Scott, L. Dantis, P. Capitelli, K. Siler, S. Hilton, R. Finn, N. Kemeny, D. Kelsen, L. Kostakoglu, J. Schlom, S. Larson (1995)
Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 36 4
Y. Lee, D. Bullard, C. Wikstrand, M. Zalutsky, L. Muhlbaier, D. Bigner (1987)
Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration.Cancer research, 47 7
M. Kaminski, M. Tuck, J. Estes, A. Kolstad, C. Ross, D. Regan, Thierry Horner, V. Williams, Tina Vleisides, R. Wahl (2009)
Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results.Blood, 114
(1983)
Treatment of advanced primary hepatocellular-carcinoma by I-131-labeledanti-AFP
R. Sharkey, C. Motta-Hennessy, D. Pawlyk, Jeffry Siegel, David Goldenberg
Biodistribution and Radiation Dose Estimates for Yttrium-and Iodine-labeled Monoclonal Antibody Igg and Fragments in Nude Mice Bearing Human Colonie Tumor Xenografts1 Abstract an Anti-carcinoembryonic Antigen Murine Monoclonal Antibody Desig Nated N'p-4, and Its F(ab')3 and Fab' Fragments, Were Coup
D. Shaw, M. Khazaeli, L. Sun, J. Ghrayeb, P. Daddona, S. McKinney, A. Lobuglio (1987)
Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen.Journal of immunology, 138 12
R. Wahl, C. Parker, G. Philpott (1983)
Improved radioimaging and tumor localization with monoclonal F(ab')2.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 24 4
H. Mennel, K. Bosslet, H. Geissel, B. Bauer (2000)
Immunohistochemically visualized localisation of gangliosides Glac2 (GD3) and Gtri2 (GD2) in cells of human intracranial tumors.Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 52 4
A. Oei, R. Verheijen, M. Seiden, B. Benigno, A. Lopes, J. Soper, A. Epenetos, L. Massuger (2007)
Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium‐90‐labeled murine HMFG1 without improvement in overall survivalInternational Journal of Cancer, 120
E. Silberstein (2012)
Radioiodine: the classic theranostic agent.Seminars in nuclear medicine, 42 3
(2003)
A phase I safety and imaging study using radiofrequency ablation (RFA) followed by 131IchTNT-1/B radioimmunotherapy adjuvant treatment of hepatic metastases
K. Kramer, N. Pandit-Taskar, J. Humm, P. Zanzonico, S. Haque, I. Dunkel, S. Wolden, M. Donzelli, D. Goldman, Jason Lewis, S. Lyashchenko, Y. Khakoo, J. Carrasquillo, M. Souweidane, J. Greenfield, D. Lyden, K. Braganca, S. Gilheeney, S. Larson, N. Cheung (2018)
A phase II study of radioimmunotherapy with intraventricular 131I‐3F8 for medulloblastomaPediatric Blood & Cancer, 65
L. Hefta, M. Neumaier, J. Shively (1998)
Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs.Immunotechnology : an international journal of immunological engineering, 4 1
M. Kaminski, M. Tuck, J. Estes, A. Kolstad, C. Ross, K. Zasadny, D. Regan, P. Kison, S. Fisher, S. Kroll, R. Wahl (2005)
131I-tositumomab therapy as initial treatment for follicular lymphoma.The New England journal of medicine, 352 5
G. Köhler, C. Milstein (1975)
Continuous cultures of fused cells secreting antibody of predefined specificityNature, 256
David Gold, R. Alisauskas, R. Sharkey (1995)
Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4.Cancer research, 55 5
M. Bourdon, C. Wikstrand, H. Furthmayr, T. Matthews, D. Bigner (1983)
Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.Cancer research, 43 6
P. Riva, A. Arista, C. Sturiale, G. Moscatelli, V. Tison, M. Mariani, E. Seccamani, S. Lazzari, L. Fagioli, G. Franceschi, G. Sarti, N. Riva, P. Natali, L. Zardi, G. Scassellati (1992)
Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I‐labelled anti‐tenascin monoclonal antibody BC‐2International Journal of Cancer, 51
R. Madiyalakan, T. Sykes, S. Dharampaul, C. Sykes, R. Baum, G. Hör, A. Noujaim (1995)
Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13.Hybridoma, 14 2
N. Finkler, M. Muto, A. Kassis, K. Weadock, S. Tumeh, V. Zurawski, R. Knapp (1989)
Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer.Gynecologic oncology, 34 3
T. Liersch, J. Meller, Michael Bittrich, B. Kulle, H. Becker, D. Goldenberg (2007)
Update of Carcinoembryonic Antigen Radioimmunotherapy with 131I-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control GroupAnnals of Surgical Oncology, 14
M. Tomblyn (2012)
Radioimmunotherapy for B-cell non-hodgkin lymphomas.Cancer control : journal of the Moffitt Cancer Center, 19 3
A. Rao, G. Akabani, D. Rizzieri (2005)
Radioimmunotherapy for Non-Hodgkin's Lymphoma.Clinical medicine & research, 3 3
R. Sharkey, M. Juweid, J. Shevitz, T. Behr, R. Dunn, L. Swayne, G. Wong, R. Blumenthal, G. Griffiths, J. Siegel, S. Leung, H. Hansen, D. Goldenberg (1995)
Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.Cancer research, 55 23 Suppl
O. Press, A. Farr, Borroz Ki, S. Anderson, P. Martin (1989)
Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.Cancer research, 49 17
A. Marquez, R. Wu, Jianxin Zhao, Jianhua Tao, Zuorong Shi (2004)
Evaluation of Epidermal Growth Factor Receptor (EGFR) by Chromogenic In Situ: Hybridization (CISH™) and Immunohistochemistry (IHC) in Archival Gliomas Using Bright-Field MicroscopyDiagnostic Molecular Pathology, 13
P. Riva, Agostino Arista, Giancarlo Franceschi, M. Frattarelli, C. Sturiale, N. Riva, M. Casi, R. Rossitti (1995)
Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors.Cancer research, 55 23 Suppl
D Colcher, D Milenic, P Ferroni, J Carrasquillo, J Reynolds, M Roselli (1990)
Invivo fate of monoclonal-antibody B723 in patients with colorectal-cancerJ Nucl Med, 31
M. Kaminski, K. Zasadny, I. Francis, M. Fenner, C. Ross, A. Milik, J. Estes, M. Tuck, D. Regan, S. Fisher, S. Glenn, R. Wahl (1996)
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 7
R. Blumenthal, R. Sharkey, D. Goldenberg (1992)
Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression.Journal of the National Cancer Institute, 84 6
Eradication of cancer still remains an upsetting issue despite our increased understanding of the molecular basis of carcinogenesis. Factors such as the molecular heterogeneity of some tumours and initial diagnosis at advanced stages hamper effective disease treatment. Given the ineffectiveness of current treatments, the development of newer therapeutic modalities to address clinical unmet needs is still mandatory. Radioimmunotherapy (RIT) that combines the use of specific antibodies against tumour-associated antigens with the cytotoxic properties of therapeutic radionuclides is amongst those approaches. The potential of monoclonal antibodies to complement current treatment protocols may bring a significant improvement to the overall therapeutic outcomes of oncologic disorders. RIT permits the delivery of a high dose of therapeutic radiation to cancer cells, while minimizing the exposure of normal cells. 131I and 90Y have been used in > 95% of clinical RIT trials and represent the current standard to which all other radionuclides are compared. Both β-particle-emitting isotopes qualify for RIT because of their favourable emission characteristics and availability and flexible radiochemistry. The importance of radioiodine in nuclear medicine together with the success of radioiodinated antibody-based drugs in the clinical setup prompted us to provide an updated overview of the application of radioiodinated antibodies in RIT and anticipate potential relevant accomplishments in the near future.
Clinical and Translational Imaging – Springer Journals
Published: Apr 1, 2022
Keywords: Antibodies; Hematologic malignancies; Radioimmunotherapy; Radioiodine; Solid tumours
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.